RxDoctor Payments Data

Ross Simpson, MD

Cardiovascular Disease · Chapel Hill, NCNPI 1972678720

Payments from drug & device makers

$24,000in general payments, 2019–2025

Across 34 payments — averaging $705.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$8K
  • Pfizer$6K
  • Amarin Pharma, Inc.$6K
  • Amgen$2K
  • Merck$1K
  • Regeneron$43
  • plus $43 from 2 others

What the payments were for

  • Consulting fees$18,20085%
  • Travel & lodging$2,55412%
  • Food & beverage$7574%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,000 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$87,252
Medicare patients
2,443
Services billed
3,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab223$268,686
EliquisApixaban82$79,751
Praluent PenAlirocumab54$61,546
EntrestoSacubitril/Valsartan11$13,672
BrilintaTicagrelor12$12,986
VascepaIcosapent Ethyl19$11,127
Ezetimibe218$4,394
Rosuvastatin Calcium213$2,691
Icosapent Ethyl28$2,487
Omega-3 Acid Ethyl Esters22$2,173
Losartan Potassium141$1,904
Metoprolol Succinate128$1,544
Prasugrel Hcl16$1,474
Atorvastatin Calcium157$1,307
Furosemide101$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,276$79,75182 claims
NovartisEntresto$29$13,67211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →